Professor Jonathan Kimmelman, Director of the Biomedical Ethics Unit, participated in a Globe and Mail panel on stem cells.
Professor Jonathan Kimmelman, Director of the Biomedical Ethics Unit, is among the experts quoted by The Globe and Mail.
The European Joint Programme on Rare Diseases (EJP RD) has granted 1.6 million euros in support of an international research collaboration specific to the ultra-rare genetic disease, Schinzel-Giedion Syndrome (SGS). The international team of researchers is coordinated by the Douglas Research Centre and º«¹úÂãÎè’s Associate Professor and Canada Research Chair in Psychiatric Genetics, The EJP RD is a joint program between major funding bodies from over 25 countries, including the CIHR and FRQS.

Providing excellent care and the latest research to help patients
The Brain Tumour Foundation of Canada estimates that 27 Canadians a day are diagnosed with a brain tumour and 55,000 are living with one. This Brain Tumour Awareness Week we recognize the toll this disease takes on patients and the work being done to improve their quality of life.

Industry and academia team up for the benefit of people suffering from ALS
A unique industry-academia partnership will increase the rate at which promising drug compounds can be tested as potential treatments for amyotrophic lateral sclerosis (ALS), a disease with no known cure that affects 200,000 people worldwide.
The partnership between The Montreal Neurological Institute and Hospital (MNI) and Takeda Pharmaceutical Company Limited (Takeda) will allow compounds developed by Takeda scientists to be tested on cell lines produced at the MNI.

Microglia, critical to Alzheimer’s research, can now be produced artificially
The quest for better understanding of Alzheimer’s disease (AD) has a powerful new tool at its disposal — the ability to artificially generate brain cells that have been shown to play an important role in the disease function.

Two researchers at the Montreal Neurological Institute and Hospital (MNI) of º«¹úÂãÎè have received funding to study a devastating neurodegenerative disease that first appears in toddlers just as they are beginning to walk.

Millions of Canadians are affected by diseases of the brain such as ALS, Parkinson’s and brain tumours, for which there are limited treatments and no cures. By 2020, neurological conditions will become the leading cause of death and disability.